Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy

Journal of Nuclear Medicine

Volumn 45, Issue 9, 2004, Pages 1480-1487

  Dimitrakopoulou Strauss, Antonia ^a   Strauss, Ludwig G ^a   Burger, Cyrill ^b   Rühl, Anne ^c   Irngartinger, Gisela ^a   Stremmel, Wolfgang ^d   Rudi, Jochen ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

18F FDG; Colorectal tumor; Survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FOLFOX PROTOCOL; PLATINUM COMPLEX; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; COMPARTMENT MODEL; FOLLOW UP; HUMAN; IMAGE ANALYSIS; KINETICS; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ALGORITHM; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; DISEASE FREE SURVIVAL; METHODOLOGY; MORTALITY; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SURVIVAL; VALIDATION STUDY;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KINETICS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 6944222538     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32:623-648.
2. Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol. 1998;224:509-522.
3. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 1996;7:95-98.
4. 18F)fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Nucl Med Biol. 1990;3:273-279.
5. Kontaxakis G, Strauss LG, Tzanakos GS. An efficient implementation of the iterative ML-EM image reconstruction algorithm for PET on a Pentium PC platform. J Comput Info Technol. 1999;7:153-163.
6. Strauss LG, Kontaxakis G, Dimitrakopoulou-Strauss A. Performance characteristics of iterative image reconstruction techniques for routine use in Positron Emission Tomography. Alasbimn J [serial online]. 2001;13. Available at: http://www.alasbimnjournal.cl/revistas/13/strauss.html. Accessed June 8, 2004.
7. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A Java environment for medical image data analysis: initial application for brain PET quantitation. Med Inform. 1998;23:207-214.
8. Burger C, Buck A. Requirements and implementations of a flexible kinetic modeling tool. J Nucl Med. 1997;38:1818-1823.
9. Phelps ME, Huang S-C, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)-2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-388.
10. Peitgen HO, Juergens H, Saupe D. Length, area and dimension: measuring complexity and scaling properties. In: Peitgen HO, Juergens H, Saupe D, eds. Chaos and Fractals. 1st ed. New York, NY: Springer; 1992:192-199.
11. Dimitrakopoulou-Strauss A, Strauss LG, Mikolajczyk K, et al. On the fractal nature of positron emission tomography (PET) studies. World J Nucl Med. 2003;4:306-313.
12. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with and without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
13. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, et al. Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. J Nucl Med. 1998;39:465-473.
14. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med. 1998;39:1197-1202.
15. 18F-Labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer. 1998;83:245-253.
16. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065.
17. Römer W, Hanauske A-R, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;12:4464-4471.
18. Freedman NMT, Sundaram SK, Kurdziel K, et al. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med. 2003;30:46-53.
19. Keiding S, Munk OL, Schiott KM, Hansen SB. Dynamic 2-(F-18)fluoro-2- deoxy-D-glucose positron emission tomography of liver tumours without blood sampling. Eur J Nucl Med. 2000;27:407-412.
20. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring glucose utilization of thoracic and abdominal organs. J Nucl Med. 1991;32:1432-1438.
21. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med. 2003;47:8-13.
22. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med. 1992;33:333-339.
23. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring or tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700-708.